MDA-MB-468 (ATCC® HTB-132)

Organism: Homo sapiens, human  /  Tissue: mammary gland/breast; derived from metastatic site: pleural effusion  /  Disease: adenocarcinoma

Permits and Restrictions

View Permits View Restrictions

Organism Homo sapiens, human
Tissue
mammary gland/breast; derived from metastatic site: pleural effusion
Product Format frozen
Morphology epithelial
Culture Properties adherent
Biosafety Level 1

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.

Disease adenocarcinoma
Age 51 years
Gender female
Ethnicity Black
Applications
This cell line is a suitable transfection host.
Storage Conditions liquid nitrogen vapor phase
Karyotype modal number = 64; range = 60 to 67.
The cell line is aneuploid human, presumably female (X, abnormal X) with most chromosome counts in the hypotriploid range.; Normal chromosomes X, N2, N3, N7, N8, N10, and N22 are clearly under-represented due to their involvement in the formation of the many marker (19) chromosomes present in this cell line.; A normal chromosome N1 (or two) is identified in each karyotype, but, in addition, regions of chromosome N1 are also present in five different marker chromosomes.; Variation is evident in the normal and marker chromosome copy number from karyotype to karyotype.
Images
Derivation
The MDA-MB-468 cell line was isolated in 1977 by R. Cailleau, et al., from a pleural effusion of a 51-year-old Black female patient with metastatic adenocarcinoma of the breast.
Clinical Data
51 years
Although the tissue donor was heterozygous for the G6PD alleles, the cell line consistently showed only the G6PD A phenotype.
Black
female

Antigen Expression

Blood Type AB; HLA Aw23, Aw30, B27, Bw35, Cw2, Cw4 (patient)

Receptor Expression

epidermal growth factor (EGF); transforming growth factor alpha (TGF alpha)

Tumorigenic Yes
Effects
Yes, in nude mice inoculated subcutaneously with 10(7) cells.
Comments
Although the tissue donor was heterozygous for the G6PD alleles, the cell line consistently showed only the G6PD A phenotype. There is a G -> A mutation in codon 273 of the p53 gene resulting in an Arg -> His substitution. EGF receptor is present at 1 X 106 per cell.
Complete Growth Medium The base medium for this cell line is ATCC-formulated Leibovitz's L-15 Medium, Catalog No. 30-2008. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.

(Note: The L-15 medium formulation was devised for use in a free gas exchange with atmospheric air. A CO2 and air mixture is detrimental to cells when using this medium for cultivation)


Subculturing Volumes are given for a 75 cmflask. Increase or decrease the amount of dissociation medium needed proportionally for culture vessels of other sizes. Corning® T-75 flasks (catalog #430641) are recommended for subculturing this product.
  1. Remove and discard culture medium.
  2. Briefly rinse the cell layer with 0.25% (w/v) Trypsin- 0.53 mM EDTA solution to remove all traces of serum that contains trypsin inhibitor.
  3. Add 2.0 to 3.0 mL of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
    Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.
  4. Add 6.0 to 8.0 mL of complete growth medium and aspirate cells by gently pipetting.
  5. Add appropriate aliquots of the cell suspension to new culture vessels.
  6. Incubate cultures at 37°C.
    Subcultivation Ratio: A subcultivation ratio of 1:2 to 1:4 is recommended
    Medium Renewal: 2 to 3 times per week
    Cryopreservation
    Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
    Storage temperature: liquid nitrogen vapor phase
    Culture Conditions
    Atmosphere: air, 100%
    Temperature: 37°C
    STR Profile
    Amelogenin: X
    CSF1PO: 12
    D13S317: 12
    D16S539: 9
    D5S818: 12
    D7S820: 8
    THO1: 7
    TPOX: 8,9
    vWA: 18
    Isoenzymes
    AK-1, 1
    ES-D, 1
    G6PD, A
    GLO-I, 1-2
    Me-2, 1-2
    PGM1, 1
    PGM3, 2
    Name of Depositor R Cailleau
    Year of Origin 1977
    References

    Brinkley BR, et al. Variations in cell form and cytoskeleton in human breast carcinoma cells in vitro. Cancer Res. 40: 3118-3129, 1980. PubMed: 7000337

    Siciliano MJ, et al. Mutually exclusive genetic signatures of human breast tumor cell lines with a common chromosomal marker. Cancer Res. 39: 919-922, 1979. PubMed: 427779

    Pathak S, et al. A human breast adenocarcinoma with chromosome and isoenzyme markers similar to those of the HeLa line. J. Natl. Cancer Inst. 62: 263-271, 1979. PubMed: 283262

    Cailleau R, et al. Long-term human breast carcinoma cell lines of metastatic origin: preliminary characterization. In Vitro 14: 911-915, 1978. PubMed: 730202

    Nigro JM, et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 342: 705-707, 1989. PubMed: 2531845

    Bates SE, et al. Expression of the transforming growth factor-alpha/epidermal growth factor receptor pathway in normal human breast epithelial cells. Endocrinology 126: 596-607, 1990. PubMed: 2294006

    Avila MA, et al. Quercetin mediates the down-regulation of mutant p53 in the human breast cancer cell line MDA-MB468. Cancer Res. 54: 2424-2428, 1994. PubMed: 8162591

    Littlewood-Evans AJ, et al. The osteoclast-associated protease cathepsin K is expressed in human breast carcinoma. Cancer Res. 57: 5386-5390, 1997. PubMed: 9393764

    Zamora-Leon SP, et al. Expression of the fructose transporter GLUT5 in human breast cancer. Proc. Natl. Acad. Sci. USA 93: 1847-1852, 1996. PubMed: 8700847

    Tumors developed within 21 days at 100% frequency (5/5).

    Notice: Necessary PermitsPermits

    These permits may be required for shipping this product:

    • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
    Basic Documentation
    Other Documentation
    FAQ's
    1. HTB-132 normal growth and morphology


      Date Updated: 2/21/2014

    Restrictions

    Unless the Purchaser has a separate license agreement with The University of Texas M. D. Anderson Cancer Center (“Institution”), the ATCC Material is subject to the following restrictions:

    1. The ATCC Material (and any Modifications, Unmodified Derivatives and/or Progeny thereof) may not be used (1) for commercial purposes or Commercial Use by any Purchaser, or (2) by for-profit or commercial entities for any purpose, provided, however, that ATCC Material that is purchased from ATCC as deoxyribonucleic acid and/or ribonucleic acid or nucleotide chains of any length (hereinafter, “Nucleic Acids”) may be used for internal research purposes by any Purchaser of Nucleic Acids;
    2. Purchaser may not transfer ATCC Materials, Modifications, Unmodified Derivatives, or Progeny to any for-profit entity or commercial entity; and
    3. Purchaser may not use ATCC Materials (or any Modifications, Unmodified Derivatives and/or Progeny thereof) in connection with any research, collaboration or other activities involving a third party that is a commercial entity or for-profit entity.

    The restrictions set forth above are in addition to the restrictions set forth in the ATCC Material Transfer Agreement. Capitalized terms have the meanings set forth in the ATCC Material Transfer Agreement unless otherwise indicated above.

    For instructions on how to obtain a license from Institution, please contact Dustin J. Romine, M.A. at the Institution Office of Technology Commercialization via email at dromine@mdanderson.org.

    Purchaser acknowledges and agrees that ATCC will send Purchaser’s contact information and order details to Institution’s Office of Technology Commercialization.

    References

    Brinkley BR, et al. Variations in cell form and cytoskeleton in human breast carcinoma cells in vitro. Cancer Res. 40: 3118-3129, 1980. PubMed: 7000337

    Siciliano MJ, et al. Mutually exclusive genetic signatures of human breast tumor cell lines with a common chromosomal marker. Cancer Res. 39: 919-922, 1979. PubMed: 427779

    Pathak S, et al. A human breast adenocarcinoma with chromosome and isoenzyme markers similar to those of the HeLa line. J. Natl. Cancer Inst. 62: 263-271, 1979. PubMed: 283262

    Cailleau R, et al. Long-term human breast carcinoma cell lines of metastatic origin: preliminary characterization. In Vitro 14: 911-915, 1978. PubMed: 730202

    Nigro JM, et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 342: 705-707, 1989. PubMed: 2531845

    Bates SE, et al. Expression of the transforming growth factor-alpha/epidermal growth factor receptor pathway in normal human breast epithelial cells. Endocrinology 126: 596-607, 1990. PubMed: 2294006

    Avila MA, et al. Quercetin mediates the down-regulation of mutant p53 in the human breast cancer cell line MDA-MB468. Cancer Res. 54: 2424-2428, 1994. PubMed: 8162591

    Littlewood-Evans AJ, et al. The osteoclast-associated protease cathepsin K is expressed in human breast carcinoma. Cancer Res. 57: 5386-5390, 1997. PubMed: 9393764

    Zamora-Leon SP, et al. Expression of the fructose transporter GLUT5 in human breast cancer. Proc. Natl. Acad. Sci. USA 93: 1847-1852, 1996. PubMed: 8700847

    Tumors developed within 21 days at 100% frequency (5/5).